FORMOSA PHARMACEUTICALS , INC
Area: CDMO
Booth No: N/A
Website: https://www.formosapharma.com
Exhibitor Profile
Formosa Pharmaceuticals (6838.TW), founded in 2010, is a clinical stage biotechnology company with assets in ophthalmology, oncology.
Our Business Development Goals:
* APP13007 (Ophthalmic Nanosuspension for Inflammation and Pain after Ocular Surgery) [US FDA approved]
* TSY-0110 (ADC biosimilar of Kadcyla (T-DM1)) [Late-preclinical stage]
* APNT® Nanoparticle Formulation Platform [Druggability validated]
* Co-development or strategic in-license ADC novel agents and ophthamology assets
Brands
FORMOSA PHARMACEUTICALS , INC
Video
Exhibit Products
-
APP13007 - Clobetasol Propionate Ophthalmic Suspension 0.05% for the treatment of post-operative inflammation and pain following ocular surgery
-
TSY-0110 - Kadcyla (T-DM1) Biosimilar
-
APNT Nanoparticle Formulation Platform
-
APP13002 - Infectious Eye Diseases Treatment
Exhibitor Press Release
- Formosa Pharma and Medvisis Announce Licensing for Clobetasol Propionate Ophthalmic Suspension 2025-04-05
- Cipla and Formosa sign multi-regional licensing deal for Clobetasol Suspension 2025-04-05
- Formosa Pharmaceuticals Announces Successful Top-Line Results from CPN-303 2025-04-05
Exhibitors you may be interested in
Highest Rated